For this final episode of 2023, we welcome back regular contributor Chris Bender from the OPTICS clinical team to pick up our conversation about GLP-1 weight loss medications. With the FDA approval of Zepbound (or tirzepatide) for weight loss in November, the profile of these potent and high-profile medications only continues to rise. We take a closer look at tirzepatide- how it compares to semaglutide, what the clinical data shows for its potency, and what promise it shows for obese and overweight patients. We also discuss some exciting new weight loss medications in development and what all this new drug development and approval could mean for the future of bariatric surgery. Referenced in Show/Further Reading: PodcastRx Episode 36: GLP-1 Agonists and Weight Loss: A Closer Look with Chris Bender, Pharm. D., BCACP "Tirzepatide Once Weekly for th ...